StemCell Therapy

A rating of 81 puts Codexis, Inc. (CDXS) near the top of the Biotechnology industry according to InvestorsObserver. Codexis, Inc.'s score of 81 means it scores higher than 81% of stocks in the industry. Codexis, Inc. also received an overall rating of 64, putting it above 64% of all stocks. Biotechnology is ranked 33 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Codexis, Inc. (CDXS) stock is trading at $26.13 as of 10:16 AM on Tuesday, Feb 2, a rise of $2.22, or 9.28% from the previous closing price of $23.91. The stock has traded between $24.93 and $26.71 so far today. Volume today is light. So far 253,983 shares have traded compared to average volume of 799,470 shares.

Click Here to get the full Stock Score Report on Codexis, Inc. (CDXS) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read more:
Is Codexis, Inc. (CDXS) the Top Pick in the Biotechnology Industry? - InvestorsObserver

This entry was posted on February 3, 2021 at 8:50 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |